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Abstract 
 
 
 
Introduction:  
There is conflicting data on the value of single photon emission tomography 
(SPECT) for the diagnosis of neuropsychiatric SLE (NPSLE). Visual assessment 
of brain SPECT scans is the standard approach in clinical practice. However the 
definition and identification of significant changes may be limited by a high 
interobserver variability, especially in centres with limited experience. This may 
be reduced by a more objective semi-quantitative assessment. The objectives of 
this study were to determine the sensitivity and specificity of SPECT for the 
detection of NPSLE at our institution using visual assesment, to determine the 
additional value of using an objective semi-quantitative diagnostic criterion, and 
to investigate the correlation between abnormal perfusion pattern and clinical 
NPSLE classification in patients with active NPSLE. 
 
Material and methods: 
Nineteen patients with NPSLE and 19 normal controls were studied with brain 
SPECT. Scans were interpreted blindly by two nuclear medicine physicians using 
two methods; visual and semi-quantitative assessments. In the visual method, 
overall visual impression was recorded for each scan using a four point scale, 
where A=normal, B=probably normal, C=probably abnormal, and D=abnormal. In 
addition, each brain region was assigned a severity score from 0=normal 
perfusion to 3=severe hypoperfusion. In the semi-quantitative assessment, ten-
band color scale was used, and perfusion deficit was quantified on the side with 
the lower color intensity comparing to the contralateral side. A score was given to 
the region with perfusion deficit according to the difference (in color bands) 
between the two hemispheres.  
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Analysis was performed for the visual assessment method (overall impression 
and severity scores) and the semi-quantitative assessment method using a 
receiver operator characteristic (ROC) curve. Optimal cut-off points were 
determined and the accuracy of the different techniques was also compared 
statistically. Finally, the correlation was determined between the SPECT 
perfusion pattern and the clinical pattern of disease. 
 
Results: 
An ROC curve analysis for the overall visual impression resulted in an area 
under the curve of 0.76. At a cut-off point of C (probably abnormal), brain SPECT 
had 89% sensitivity and 57% specificity for the diagnosis of NPSLE. The severity 
score which include the total severity score and the modified total severity score 
resulted in areas under the curve of 0.75 and 0.79 respectively. The semi-
quantitative assessment resulted in areas under the ROC curve of 0.80. 
Statistically, there was no difference between the overall visual impression, visual 
severity scores, and the semi-quantitative assessment. Agreement analysis 
between the SPECT pattern and clinical pattern of disease showed agreement in 
91.6% in the diffuse pattern, whereas agreement in the focal pattern was seen in 
only 42.8%.  
 
 
Discussion and Conclusion: 
In this study, we found that brain SPECT is able to diagnose active NPSLE with a 
high sensitivity and moderate specificity. The overall visual impression, visual 
severity scores, and the semi-quantitative assessment showed no significant 
differences between the techniques. The use of the semi-quantitative 
assessment described may be useful in centers with limited experience in the 
interpretation of brain SPECT. The correlation between the SPECT pattern and 
clinical disease pattern may provide some insights into the pathophysiology of 
NPSLE. 
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Opsomming 
 
 
Inleiding:  
Daar is teenstrydige inligting oor die waarde van brein enkelfoton emissie 
tomografie (EFET) vir die diagnose van neuropsigiatriese SLE (NPSLE). Visuele 
beoordeling van brein EFET flikkergramme is die standaard benadering in 
kliniese praktyk. Die definisie en identifisering van betekenisvolle veranderinge 
mag egter beperk word deur ‟n hoë inte-waarnemer wisseling, veral in sentra met 
beperkte ondervinding. Dit mag verminder word deur ‟n meer objektiewe semi-
kwantitatiewe beoordeling. Die doel van hierdie studie was om 1. die sensitiwiteit 
en spesifisiteit van EFET vir die opspoor van NPSLE in ons instelling te bepaal, 
2. die bykomende waarde van ‟n objektiewe semi-kwantitatiewe diagnostiese 
kriterium vas te stel, en 3. die korrelasie tussen „n abnormale perfusiepatroon en 
„n kliniese NPSLE klassifikasie in pasiënte met aktiewe NPSLE te ondersoek. 
 
Materiaal en Metodes: 
Negentien pasiënte met NPSLE en 19 normale kontroles is met brein EFET 
bestudeer. Flikkergramme is blind deur twee kerngeneeskundiges 
geïnterpreteer, deur gebruik te maak van twee metodes, „n visuele en semi-
kwantitatiewe beoordeling. Vir elke flikkergram is ‟n globale visuele indruk 
genoteer deur gebruik te maak van „n 4-punt skaal, waar A=normaal, 
B=waarskynlik normaal, C= waarskynlik abnormaal, en D=abnormaal. Bykomend 
is „n ernstigheidsgraad waarde van 0=normale perfusie tot 3=erge hipoperfusie 
vir elke breinstreek toegeken. Vir die semi-kwantitatiewe beoordeling is „n telling 
vir streke met laer intensiteit vergeleke met die kontralaterale kant toegeken, 
volgens die verskille in kleurbande deur gebruik te maak van ‟n tienbandskaal. 
Die visuele metodes vir die globale indruk, visuele ernstigheidsgraad waarde, en 
die semi-kwantitatiewe beoordeling is geanaliseer deur ‟n relatiewe 
funksioneringskenmerk (receiver operator characteristic (ROC)) kurwe te gebruik 
en optimale afsnypunte te bepaal. Die akkuraatheid van die verskillende tegnieke 
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is ook statisties vergelyk. Laastens is die korrelasie tussen die EFET 
perfusiepatroon en die kliniese siektepatroon bepaal. 
 
Resultate: 
„n ROC kurwe analise vir die globale visuele indruk het gelei tot „n area onder die 
kurwe van 0.77. By „n afsnypunt van (C) het brein EFET „n sensitiwiteit van 89% 
en „n spesifisiteit van 57% vir die diagnose van NPSLE gehad. Die visuele 
ernstigheidsgraad telling, en die semi-kwantitatiewe beoordeling het 
onderskeidelik tot areas onder die ROC kurwe van 0.75 en 0.79 vir die visuele 
ernstigheidsgraad waarde, en 0.8 vir die semi-kwantitatiewe beoordeling gelei. 
Statisties was daar geen verskil tussen die globale visuele indruk, die visuele 
ernstigheidsgraad waarde, en die semi-kwantitatiewe beoordeling nie. 
Ooreenstemmingsanalise tussen die EFET patroon en kliniese siektepatrone het 
‟n ooreenstemming van 91.6% in die diffuse patroon getoon, terwyl die fokale 
patroon ooreenstemming van slegs 42.8% getoon het.  
 
Bespreking en Gevolgtrekkig: 
In hierdie studie is gevind dat brein EFET ‟n diagnose van NPSLE kan maak met 
„n hoë sensitiwiteit en gemiddelde spesifisiteit. Die globale visuele indruk, visuele 
ernstigheidsgraad waarde, en die semi-kwantitatiewe beoordeling wat beskryf is, 
het geen betekenisvolle verskille tussen die tegnieke getoon nie. Die gebruik van 
die semi-kwantitatiewe beoordeling wat beskryf is, mag van waarde wees in 
sentra met beperkte ondervinding in the interpretasie van brein EFET. Die 
korrelasie tussen die EFET patroon en kliniese siektepatrone mag insig gee in 
die patofisiologie van NPSLE. 
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Chapter 1 -  
 
Systemic lupus erythematosus (SLE) is a chronic inflammatory multi-organ 
disease. It is characterized by a variety of clinical features including abnormalities 
of the skin, joints, lungs, heart, kidneys, and the nervous system. The disease 
has a variable course marked by active and inactive periods.1 
 
In different studies nervous system involvement in SLE has varied from 18 to 80 
% 2 3 4 5. The diagnosis of neuropsichiatric SLE (NPSLE) is based on clinical data 
and this variation may reflect the lack uniformity in diagnostic criteria.  It occurs 
also in the majority of paediatric SLE patients at least as frequently as lupus 
glomerulonephritis. However, the actual prevalence and incidence remain 
uncertain.6 
 
Nervous system manifestations in SLE include neurological syndromes of the 
central, peripheral and autonomic nervous systems, as well as psychiatric 
syndromes. These manifestations have been given different terms, such as CNS 
lupus, neuro-lupus, lupus cerebritis, and lupus vasculitis. However, all these 
terms are inappropriate, as they do not include the wide range of the neurological 
and psychiatric complications in SLE. Therefore, the term neuropsychiatric SLE 
is considered to be more appropriate as it encompasses these manifestations.7  
 
A challenging problem in SLE is to determine whether neurological or psychiatric 
symptoms are due to lupus itself or due to secondary factors.8 Moreover, it is at 
times not easy to distinguish focal from diffuse processes by clinical 
presentation,9 and the diagnosis of CNS involvement of SLE is difficult10 due to 
the absence of a reliable laboratory investigation or an ideal imaging modality, as 
there is no „„gold standard‟‟ for the diagnosis of NPSLE.   
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Neuro-imaging methods are useful and necessary, in order to narrow the 
differential diagnosis, elucidate the underlying pathological mechanisms, identify 
anatomic foci of pathology, quantify disease activity, and determine the functional 
and prognostic consequence of NPSLE.11 Functional brain imaging using SPECT 
provides a measure of regional cerebral blood flow (rCBF) which has been 
claimed to be sensitive in detecting brain involvement in SLE.12 13 14 However, it 
has a low specificity and comparable abnormalities have been described in SLE 
patients without neuropsychiatric manifestations.15 16 
 
There are different methods to assess brain SPECT in SLE patients with 
neuropsychiatric manifestations. Currently, most nuclear medicine departments 
use visual assessment which provides a qualitative description of the deficit(s) 
seen in the images. However, the major challenge is to define and identify 
significant changes. This method is also limited by high interobserver variability 
and low reliability.17 
 
Investigators have attempted to use semi-quantitative methods to reduce the 
inter-observer variation, and to improve the detection of non-visualized lesions. 
Semi-quantitative techniques based on regions of interest provide a reasonable 
and objective measurement of relative changes in blood flow in regions of the 
brain. The regions of interest can be drawn manually, which may lead to 
variability of results, as well it is often, time-consuming and may require several 
subjective interactions on the part of the operator.18 Regions of interest can also 
be drawn semi-automatically after being spatially re-oriented into a standard 
brain space and automatically calculated and analyzed for asymmetry.19  
 
Recent developments in neuro-imaging data analysis using voxel-wise analysis 
such as statistical parametric mapping (SPM) and brain registration and analysis 
of SPECT studies (BRASS) showed an improvement in classification accuracy, 
and have been shown to be preferable over a purely visual assessment and 
volumes of interest (VOI).20 21  
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Only one study has examined a voxel-wise analysis in NPSLE, where it showed 
abnormalities in regions that could be missed using visual or VOI analysis.22 
However, this technique requires software which is not widely available, and it 
needs the creation of a template from a normal database, and requires a 
significant degree of technical skill. This makes these voxel-based techniques 
difficult to implement in an ordinary Nuclear Medicine Department. Therefore, 
instead of using voxel-wise analysis, this study examines the use of a simple 
semi-quantitative assessment by using a color scale. This approach can be 
available everywhere, without the problems associated with a voxel-based 
method. 
 
Study objectives: 
 
The primary aim of the study is to determine the sensitivity and specificity of 
SPECT for the detection of NPSLE at our institution, and to determine the 
optimal diagnostic criterion for interpretation, using a visual analysis. 
 
A secondary aim is to determine the additional value of using a simple semi-
quantitative analysis to improve the sensitivity and specificity of SPECT for the 
detection of NPSLE. 
 
A third aim is to investigate correlations between abnormal perfusion patterns 
and clinical NPSLE manifestations in patients with active NPSLE. 
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Chapter 2 - Literature Review 
 
2.1. Etiology and risk factors for neuropsychiatric SLE: 
Neuropsychiatric events in SLE may be caused by primary manifestations of the 
disease itself, or be secondary to steroid drugs, or infective, hypertensive and 
metabolic complications, or caused by coincidental problems unrelated to 
lupus.23  
 
Genetic factors like HLA-DR9 antigen and HLA-DR3 may result in susceptibility 
to the development of the neuropsychiatric features of SLE, whereas HLA-DR4 
may confer protection against the development of these features.24 CNS 
involvement in SLE is also strongly associated with the presence of 
antiphospholipid syndrome, in particular with arterial thrombosis, and with 
cutaneous vasculitic lesions. 25 
 
2.2. Pathology and pathogenesis of neuropsychiatric SLE: 
The pathogenesis of neuropsychiatric SLE is likely to be multifactorial and 
reflects a mixture of pathogenic mechanisms, which include vascular 
abnormalities, auto-antibodies, and local production of inflammatory mediators.26 
Vasculopathy of large or small vessels may either be directly responsible for the 
clinical disease or, alternatively, exert its effect by enhancing blood brain barrier 
permeability for pathogenic autoantibodies.27 
 
Several brain-specific and systemic auto-antibodies have been implicated to a 
varying extent in the pathogenesis of NPSLE.28 Antiphospholipid antibodies have 
been found to be linked to focal Neuropsychiatric (NP) disease, whereas anti-
ribosomal P antibodies and anti-NR2 antibodies were associated with diffuse 
disease. 29 
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2.3. Neurological manifestations of SLE: 
Since the first report of stupor and coma in SLE, a multitude of neuropsychiatric 
syndromes have been reported. However, the lack of uniformity in patients‟ 
diagnoses, standardization of terminology, and disease classification has 
resulted in inappropriate diagnosis and management. 
 
In 1979 Kassan and Lockshin proposed a classification system for NPSLE to 
enable better segregation of clinical subsets and the identification of the variety 
of clinical presentations such as seizure, psychosis, neuropathy, movement 
disorders.30 However, the proposed definition for SLE of the revised American 
Rheumatology Association (ARA) in 1982 accepted only seizures and 
psychosis,1 and other events find no expression in the criteria. Most investigators 
did not agree with this definition. 31 
 
In 1990, an ad hoc workshop in Canada and USA proposed diagnostic criteria for 
NPSLE including 33 items;31 subdivided into three primary categories; neurology, 
psychiatric, and laboratory. This classification system has however not been 
utilized widely, as details on the diagnostic and exclusion criteria were not 
provided. 
 
In 1999, the ACR developed a standard nomenclature and set of case definitions 
for 19 NPSLE syndromes, and patients were diagnosed to have NPSLE if they 
meet the case definition in addition to three or more of the ACR (non NPSLE) 
criteria for SLE.7 This has provided a uniform methodology for defining clinical 
subsets of patients with NP manifestations and suggests a shift in thinking about 
nervous involvement in SLE away from the concept that any nervous system 
involvement in patients with SLE can be categorized simply as NPSLE. The 
neuropsychiatric complications in SLE were classified into central nervous 
system involvement (diffuse or focal) and peripheral nervous system 
involvement.  
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Diffuse syndromes include psychosis, mood disorder, cognitive dysfunction and 
acute confusional state. These events were the most problematic, since it was 
difficult to determine whether these manifestations were due to SLE itself or due 
to psychological reaction to the stress of having chronic illness. Focal syndromes 
include cerebrovascular disease, demyelinating syndrome, headache, a septic 
meningitis, chorea, seizures, and myelopathy. Peripheral nervous system 
involvement includes Guillian-Barre syndrome, myasthenia gravis, autonomic 
disorder, mononeuropathy, plexopathy and polyneuropathy.7  
 
As with other organ involvement in SLE, nervous system disease may occur at 
any time in the disease course, but most of the events were seen early and in 40 
% of the group occurred before or at the time of SLE diagnosis,2 and these 
events may present as single or multiple neurological events in the same 
individual. 5 
 
Neuropsychiatric events in SLE patients occur commonly in multi-system 
involvement, which provides support for the notion these events are most likely 
due to lupus. However, nervous system disease in SLE can occur even without 
multi-system involvement. 32 
 
The clinical outcome of SLE revealed increased disability and mortality among 
patients with NPSLE, 33 which is considered as being worse in South Africa than 
in Western countries.34 Moreover, the outcome is significantly worse for NP 
events attributed to primary SLE compared to secondary causes such as 
steroids.35 The outcome is also worse with focal syndromes which lead to 
permanent and irreversible changes, while reversible changes are common with 
diffuse syndromes.36 The outcome is also worse with a complex event compared 
to isolated events.8 
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2.4. Diagnosis of neuropsychiatric SLE: 
The management of NPSLE requires the presence of cerebral lupus to be 
established and its severity to be assessed, but the diagnosis of CNS 
involvement in SLE is difficult. In reviewing the extensive range of immuno-
serological, electrophysiological, and neuro-imaging techniques that have been 
investigated as possible markers of CNS lupus, it is apparent that there is still no 
single test which is diagnostic.10 
 
The detection of auto-antibodies is not routinely utilized as a diagnostic marker 
for NPSLE, because their association with disease remains highly contentious.37 
Cerebrospinal fluid (CSF) abnormalities are commonly found but are non-
specific, as is EEG, which is of little diagnostic value in neuropsychiatric lupus.15 
 
Structural imaging modalities were found to be useful in evaluating patients with 
focal syndromes. However, they are insensitive in non-focal presentations such 
as depression and cognitive disorders.38 Magnetic resonance imaging (MRI) is 
more sensitive than CT in demonstrating particular morphological abnormalities, 
but the poor specificity of the lesions found on MRI prevents the diagnosis of 
NPSLE being made from radiological findings alone.  Another drawback of MRI is 
the difficulty in differentiating active CNS manifestations from old inactive 
lesions.39 
  
Since the first use of Oxygen-15 in 1975,40 functional imaging using Positron 
emission tomography (PET) and SPECT have started to play a role in SLE 
patients with NP manifestations. PET is considered to be a sensitive and reliable 
method for evaluating SLE patients with CNS involvement. This was 
demonstrated by Meyer et al. where FDG PET showed abnormal perfusion and 
metabolism in all patients.41 Similar results have been found in a study done by 
Weiner et al,42 but the usefulness of PET is considerably reduced by its high 
cost,38 and lack of availability. 
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2.5. Single photon emission tomography (SPECT): 
 
Since SPECT was introduced in the early 1980s as a method for evaluating 
cerebral blood flow, it has continued to provide useful information and a better 
understanding of the clinical presentation of numerous neuropsychiatric 
conditions such as dementia, stroke, psychiatric disorders, epilepsy,43 HIV 
dementia,44 as well as in NPSLE.12 13 14 The role of SPECT in NPSLE will be 
discussed in the next section.  
 
The principle of SPECT brain imaging is governed by the brain blood barrier 
(BBB), which excludes many substances from entering the brain from the blood. 
Radiopharmaceuticals for brain imaging can be broadly grouped into two 
categories: diffusible tracers, which are lipophilic and readily cross the BBB and 
non-diffusible tracers, which are hydrophilic and cannot cross the BBB.45 
Cerebral perfusion studies are performed using the former group. 
 
Several radiopharmaceuticals have been used for the assessment of cerebral 
perfusion in NPSLE patients. 123I-iodoamphetamine seems to be useful to identify 
active CNS involvement; 46 however, it is limited by its lack of cost effectiveness 
and availability in many parts of the world, including South Africa. 
 
The development of the technetium-99m-hexamethylpropylene amine oxine    
(99mTc HMPAO) has offered the clinical community a safe, effective and sensitive 
technique for evaluating regional cerebral blood flow, as it is deposition in the 
brain is proportional to the cerebral blood flow. However, its rapid decomposition 
in vitro necessitates its administration within 30 minutes of preparation. On the 
other hand technetium-99m-ethyl cysteinate dimer (99mTc ECD) has a better in 
vitro stability and brain-to-background ratio, resulting in a slightly better image 
quality.47 
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2.5.1. Clinical applications of SPECT in neuropsychiatric SLE patients: 
 
The utility of SPECT for evaluation of CNS damage in SLE patients is not clearly 
established, and many controversies exist. This section will concentrate in the 
clinical value of SPECT in NPSLE.  
 
2.5.1.1. Asymptomatic SLE patients: 
Several studies have investigated SLE patients without active NPSLE or a past 
history of neuropsychiatric manifestations, where SPECT showed hypoperfusion 
in some patients.14 These abnormalities could be explained by the transient and 
mild nature of some minor manifestations which may go undetected, or may be 
related to diffuse cerebral and extracerebral vasculopathy resulting from the 
clinical and inflammatory nature of SLE.48  
 
Alternatively, these patients may have sub-clinical CNS involvement and may 
show psychiatric symptoms in the near future.49 In addition, age and use of 
steroid medication may result in brain atrophy which may be another important 
factor that affects the interpretation of the SPECT images.50 
 
2.5.1.2. Active NPSLE patients: 
SPECT provides confirmation of clinically active CNS involvement in SLE 
patients, and it may give an objective indication of cerebral disease in patients 
with borderline clinical evidence, particularly if performed within the first four 
months after the onset of CNS involvement.51 The sensitivity of SPECT for 
detecting abnormalities in children during active CNS disease has been shown to 
be almost 100 %. This was shown by Szer et al.52 where all children had 
abnormal cerebral perfusion. This is similar to results found by Huang et al.53 
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In adult NPSLE patients, SPECT demonstrated significantly decreased cerebral 
perfusion in 70-88 % of patients during active NP manifestations.13 15 48 54 55 The 
sensitivity for detecting these abnormalities depends on the clinical subtype of 
NP manifestations, as SPECT is more sensitive for diffuse and major 
manifestations rather than focal and minor manifestations.12 56 
 
2.5.1.3. Correlation of SPECT findings with neuropsychiatric 
manifestations: 
Conflicting reports exist whether or not cerebral blood flow abnormalities 
correlate with neuropsychiatric function. Kusher et al. reported that the 
magnitude of changes in cerebral blood flow depends on the NPSLE subtype, as 
the greatest change occurred in patients with diffuse NP manifestations, whereas 
focal manifestations showed focal lesions.46 This is in agreement with Zhang et 
al.57 In addition to that, patients with more than one type of NP manifestation had 
a greater number of areas of hypoperfusion. 58 
 
In contrast, a correlation between the pattern of defects and clinical symptoms 
was not evident in the studies reported by Rubbert et al. and Kodama et al.13 49 
Furthermore, Waterloo et al. reported that there was no association between 
dysfunction in any cognitive domain and cerebral blood flow changes except 
between slowed psychomotor speed and executive dysfunction, with the parietal 
and frontal lobes respectively.59 
 
Interestingly, most patients with long standing disease showed cerebral blood 
flow abnormalities with a predominance of focal uptake defects, whereas most of 
the diffuse uptake was seen in patients with shorter disease duration.13 However, 
Nossent et al. showed that focal and diffuse defects can occur in short or long 
disease duration.54 
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Correlations between SPECT findings and some immunologic parameters were 
also studied. An association has been found between SPECT and cumulated 
tissue damage and overall disease activity measured by systemic lupus activity 
measure (SLAM) index. However, no significant relationship was found between 
the presence of the auto-antibodies and SPECT imaging findings.15 
 
2.5.1.4. Monitoring and guiding therapy: 
Once a diagnosis of NPSLE is established, the first step is to identify and treat 
potential aggravating factors such as hypertension and uremia. Symptomatic 
therapy should be considered if appropriate. Immunosuppressive therapy has 
been used to treat many NPSLE manifestations, and anticoagulant is indicated 
strongly for focal disease.23 
 
SPECT, besides helping with the diagnosis of NPSLE and starting the 
appropriate therapy, has been shown to be a very sensitive method in monitoring 
disease severity and response to treatment. Huang et al. showed that SPECT 
was consistently abnormal in children during active CNS disease, where 
improvement was seen after the symptoms resolved, suggesting the reversibility 
of the neurological disorder.53 Moreover, SPECT as a technique could detect 
abnormalities long before the development of irreversible damage, and therefore 
is useful in guiding the clinical treatment.57 However, Sun et al. thought that 
SPECT should be considered only as an independent parameter to help in 
evaluating the therapeutic effect only if the clinical and serological examinations 
are controversial or discrepant.60 
 
2.5.1.5. Prognosis: 
SPECT seems to be useful in determining the prognosis of NPSLE patients. 
Kodama et al. investigated this, and demonstrated that SPECT revealed 
abnormal findings during psychiatric remission, which might represent the 
presence of sub-clinical CNS involvement, and indicate poor prognosis.49 
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2.5.2. Sensitivity and specificity of SPECT versus other imaging modalities: 
The role of different neuro-imaging modalities in the diagnosis and evaluation of 
NPSLE is still controversial. SPECT has been found to be useful for the 
identification of blood flow abnormalities in patients with NPSLE, which has seen 
commonly in the frontal, parietal, and temporal lobes;14 however the sensitivity 
for detecting these abnormalities depends on the clinical subtype of NP 
manifestations. The sensitivity is very high for major CNS symptoms (90 -100 
%),13 14 compared to minor symptoms (71% - 84.6 %).13 61  The sensitivity for 
detecting diffuse symptoms is 86 %12 57 while only 33 % of focal disease was 
identified with SPECT.12 Using acetazolamide can reveal a marked reduction in 
cortical perfusion reserve, which can increase SPECT sensitivity.62 However, 
SPECT lacks specificity, as similar abnormalities were seen in patients with a 
past history of NPSLE (66.7%),15SLE patients without neuropsychiatric 
manifestations (13 -37  %), 14 48 and in other neurological conditions.43 
 
There is some evidence to suggest that SPECT may even be more sensitive 
than FDG PET in NPSLE, as detecting changes in rCBF may be superior to 
detection of changes in glucose metabolism, which can be preserved in NPSLE. 
This was demonstrated by Koa et al. where SPECT was able to detect 69 % of 
NPSLE compare to 46 % for FDG-PET.63 Another study done by Koa et al. 
showed 100 % sensitivity for SPECT and 90 % for PET.64  
 
Structural imaging such as CT and MRI have been found to be less sensitive 
than functional modalities such as SPECT and PET which can be explained by 
the fact that functional impairment may occur before structural damage develops. 
This was demonstrated by Castellino et al. where SPECT showed a sensitivity of 
90.9 %, while MRI detected only 62 % of the NPSLE patients.16 A similar result 
was found by Zhang et al. where SPECT detected up to 90 %, and MRI 45 % of 
cases. However, MRI was found to be useful with severe or advanced changes 
of NPSLE, while SPECT could be more useful for prompt diagnosis of early 
stages of the disease.57 
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2.5.3. Image analysis methods: 
Brain image analysis has been gone through many developments during the past 
years. Whereas visual image interpretation is still used in routine clinical practice 
in most centers, new techniques which allow derivation of quantitative diagnostic 
data may increase sensitivity and specificity. These, however are not widely 
available. 
 
2.5.3.1. Visual image analysis: 
The visual image interpretation using a variety of grey and color scales remains 
the first step for any nuclear medicine physician. Most of the observers use one 
of a number of color scales, which often increase an observer‟s sensitivity to 
detect small changes in activity compared to using a grey scale, however color 
scales can introduce false “edges” that may lead to the over interpretation of 
small changes as being significant. 65 Color scales can be regarded as belonging 
to one of two categories. The first category includes colors that have a 
continuous variation in color with changing intensity. The second group are color 
scales that give discrete color levels with changing intensity.66 
Different approaches have been used to determine cerebral perfusion 
abnormalities in NPSLE patients using visual assessment. The commonest one 
is by identify any areas of hypoperfusion or asymmetry in the distribution of the 
tracer57 58 67. Some observers preferred to consider a scan positive only when 
these abnormalities were seen on at least two consecutive slices, 12 16 51 or even 
when abnormal defects were present in almost six slices.15 In one study, a scan 
was considered abnormal if there is visible difference of at least of two colors 
compared to the contralateral side.13 Another approach defined the pattern of 
uptake as a focal defect when it is was visible in two consecutive slices, while 
more than two slices was considered to be a diffuse uptake defect. 13  However 
Lin et al. defined a focal pattern when a single lesion or multiple small lesions 
were confined to one or two lobes, while lesions involving three or more lobes 
were considered to be a diffuse pattern.14 
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Whatever the choices of visual analysis, these methods are limited by a high 
inter observer variability and low reliability.20 Therefore, quantitative analysis 
using different techniques have been investigated for a more accurate and 
observer – independent image interpretation. 
 
2.5.3.2. Quantitative analysis: 
The advancement of technology allows the assessment of brain perfusion in a 
quantitative way, resulting in lowering of the variability across the different 
nuclear medicine departments and enhancing the consistency of image 
interpretation independent of reader experience. This approach provides the best 
way for unbiased comparison of multiple investigations in the same patient or for 
the comparison of an individual investigation with normal or control studies.68 
These quantitative analysis methods are divided mainly into two groups: 
(1) Absolute quantification 
(2) Semi-quantitative analysis   
 
2.5.3.2.1. Absolute quantification: 
An absolute quantification of regional cerebral blood flow should be more 
objective and may reduce the inter-subject or even the intra-subject variation. 
However, it is not practical for routine clinical use because it requires arterial 
blood sampling, careful correction for attenuation, complex modeling of enzyme 
kinetics, and in vitro measurements of blood samples.63 
 
2.5.3.2.2. Semi-quantitative analysis: 
Several approaches have been presented for semi-quantitative analysis 
comparing images of patients with a normal population. Some require creating a 
normal brain perfusion database, to be able to detect an abnormal perfusion 
pattern, by using different approaches based on (1) image standardization (2) a 
statistical model for evaluating significance.69 
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2.5.3.2.3. Image standardization  
This is a technique to transform the brain image of an individual subject into a 
standard steriotactic brain space, e.g. Talarach space. The main aim of 
registration is to establish an exact correspondence between the voxels of 
different studies across different patients, making direct comparison possible. 
Although manual alignment of images is possible, it is time consuming and lacks 
reproducibility. Therefore, automated registration is highly desirable.70 
Standardized images can be used for image averaging to decrease variation in 
image intensity.71 
  
2.5.3.2.4. Statistical models: 
Once standardized image data have been obtained, a number of programs using 
different statistical models exist to compare patient images with a normal brain 
image. These programs include regions or voxels of interest (ROI/VOI) and 
voxel-wise analysis. 
 
2.5.3.2.4.1. Voxel–wise analysis: 
Recent developments in neuro-imaging data analysis use voxel based analysis to 
reduce observer subjectivity inherent in visual analysis, by using various software 
packages such as SPM and BRASS. This approach has the advantage of 
including the rCBF information for the whole brain for statistical analysis without 
any a priori hypothesis regarding the regions possibly involved, which could 
result in a better characterization of rCBF differences in brain regions while also 
reducing the operator‟s subjectivity.72  
 
SPM has been successfully applied to identify the distribution of functional 
abnormalities in patients with dementia and depression 73 as well as in evaluating 
the severity of aphasia.74 BRASS has also been applied in some neurological 
disease such as Parkinson‟s syndrome, 75 Alzheimer‟s disease,76 77 traumatic 
brain injury, and in patients with cognitive impairment.20 
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A single study of SPECT using SPM was used in NPSLE patients to evaluate 
rCBF objectively, and the relationship between the rCBF and the psychiatric 
symptoms. This study showed no significant areas of decreased perfusion in SLE 
patients without psychiatric symptoms in comparison with a control group. On the 
other hand, SLE patients with major psychiatric symptoms demonstrated reduced 
perfusion in the posterior cingulate gyrus. Abnormalities in this region could be 
missed using a visual or VOI analysis.22 
 
Quantified analysis of functional brain images would ideally be made on a voxel-
wise basis. Although a voxel-wise comparison is theoretically relatively simple, it 
can present a number of challenges including unavailability of software, and 
normal data. In addition, skilled staffs are required to implement the software 
correctly.78 This may go some way to explain why these techniques are not in 
more widespread use. It is therefore, worthwhile to explore methods that are 
widely available, and simpler to implement. 
 
2.5.1.2.4.1. ROI and VOI analysis: 
With this technique, regions of interest can be drawn manually, which may lead 
to variability of results, or can be drawn semi automatically after being spatially 
re-oriented into a standard brain space and automatically calculated and 
analyzed for asymmetry. Nearly all SPECT camera suppliers offer software for 
ROI techniques. Standard software normally offers a left-to-right hemisphere and 
anterior-to-posterior comparison showing maximum, minimum, and average 
count rates.19  
 
A semi-quantitative approach based on VOI had been used to measure regional 
CBF in NPSLE patients. This was used by Waterloo et al. where the regional 
CBF was performed with an automated computer program, and semi-
quantitatively measuring the blood perfusion in 16 symmetrical sectors of the 
brain. A reduction in rCBF of greater than 15 % relative to the visual cortex was 
considered abnormal.59  
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Nossent et al. defined first the region with decreased perfusion visually, and 
uptake in each region was divided by the uptake in the same region of the 
contralateral side. Ratios below 0.95 were considered as abnormal.54 Sanna et 
al. divided the brain into six circular regions of interest (ROI), and an index of 
asymmetry was expressed according to a specific formula. Pathological cases 
had an index asymmetry of > 6, while the index asymmetry in the control group 
was less than 5.78.15  
 
VOI based methods seem to be useful to identify areas of hypoperfusion, as well 
as following disease progression.58 However, Liu et al. suggested that these 
methods are not valid for SLE patients with brain involvement, since brain lesions 
in SLE are always multifocal and can be symmetrical and therefore, calculating 
ROI relative to the contralateral side or to the cortex may not be useful.79 In 
addition to that, semi-quantification based on ROI requires visual interpretation 
and several subjective interactions to identified regions with reduced perfusion 
before using this method.18  
 
Whatever the choice of analysis, (visual, semi-quantitative, or absolute 
quantitative analysis) it is important to realize that functional imaging is 
influenced by the kinetics of the tracer, the energy of the gamma photon, the 
imaging detector system, the reconstruction algorithm and the algorithm 
calculating the functional parameter.78 
 
A simple semi-quantitative approach based on the use of a standard color scale 
in a defined way may significantly enhance visual interpretation, while being 
available everywhere, easy to implement, and not relying on having access to a 
normal database. 
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6. Hypothesis: 
Our hypothesis is that:  
 
(1) Visual assessment of SPECT scans can discriminate between patients with 
clinically active NPSLE and a control group with no previous history of SLE or 
NPSLE. 
 
(2) The distinction of NPSLE patients and controls using brain SPECT can be 
significantly enhanced using a simple semi-quantitative analysis technique. 
 
(3) In patients with active NPSLE, correlations exist between abnormal perfusion 
patterns and clinical NPSLE manifestations.  
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Chapter 3 - Material and Methods 
 
3.1. Study design: 
This was a retrospective, controlled, descriptive and analytic study in which 
patients with neuropsychiatric SLE were compared to a normal control group. 
 
3.2. Study population: 
 
 
3.2.1 Neuropsychiatric SLE (NPSLE) group: 
 
We reviewed the charts of 200 SLE patients seen by the Rheumatology Division 
in Tygerberg Hospital, during the period of 1995-2009, and from the electronic 
database of the Nuclear Medicine department, we selected 19 patients who had 
undergone brain SPECT and had active NPSLE disease during the time that they 
had the scan. 
 
Data on gender, age, disease duration, and clinical manifestations was collected 
for each patient from the patient record and was reviewed with an expert 
Rheumatologist from the Rheumatology unit. 
 
Patients with active NPSLE were defined by the new onset or persistence of 
neurological manifestations at the time of SPECT scanning. Patients were 
subdivided into two groups: 
 
(A) Patients with diffuse NPSLE syndromes (acute confusional state, cognitive 
dysfunction, mood disorders, anxiety disorders, and psychosis) 
 
(B) Patients with focal NPSLE syndromes (stroke, seizures, cranial nerve palsy, 
demyelinating syndrome, aseptic meningitis, and movement disorders). If the 
patient had both diffuse and focal CNS disease, that patient was designated as 
having diffuse disease. 
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3.2.1.1 Inclusion criteria: 
Each patient had to fulfill certain criteria, which were: 
 
1. American college of rheumatology (ACR) criteria for the diagnosis of SLE (four 
criteria or more) (Appendix 1). 
 
2. Patients with active changes in neurological or psychiatric function in the 
history or physical examination as defined by the American college of 
rheumatology criteria. 
 
3.2.1.2 Exclusion criteria: 
Patients with any of the following criteria were excluded from the study: 
 
1. Head neoplasm 
2. History of head injury 
3. Diabetes mellitus 
4. History of alcohol or drug abuse 
5. History of dementia 
 
3.2.2 Control group: 
The control group was made up of 19 normal healthy subjects who were selected 
from the electronic database at Nuclear Medicine department at Tygerberg 
Hospital. This group was studied by brain SPECT as part of a previous research 
project, where they initially underwent a physical examination and a psychiatric 
screening interview with the Mini International Neuropsychiatric Interview 
(Version 4.4). All healthy volunteers were examined by magnetic resonance 
imaging (MRI) scan, which had been reported by an expert radiologist to rule out 
any pathology. Only individuals without abnormalities on these screening tests 
and MRI were included in this group.  
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3.3. SPECT imaging: 
 
Thirty-seven patients were injected with 99mTc-HMPAO intravenously with a dose 
ranging from 550 to 740 MBq. One patient was injected with 99mTc-ECD. The 
injection was done after establishing a lipophilic species of at least 80 %. 
 
Imaging was performed using a dual headed gamma camera equipped with fan 
beam collimators. Thirty-three scans were obtained using an Elscint Helix 
(General Electric Medical Systems USA), while five scans were obtained using 
an Infinia (General Electric Medical Systems USA). Projections were acquired 
with three -degree intervals over 360 degree (120 projections for each head), and 
20 seconds per projection. 
 
Acquisition was acquired using a 128 × 128 matrix. Collimators were positioned 
as close as possible to the patient‟s head. The average radius of rotation was 
14.7 cm. Approximately 3.5 million counts were obtained for all, but three studies 
the obtained counts were 1.6, 2.3 and 2.4 million counts. 
 
Projection data were reviewed in cinematic display prior to reconstruction to 
ensure the absence of motion artifacts, and to ensure that the entire brain was in 
the field of view. In the event of those problems being present, data acquisition 
was repeated. 
 
All SPECT studies were reconstructed on a Hermes system (Nuclear Diagnostic, 
Sweden) with an ordered subsets expectation maximization (OSEM) iterative 
algorithm (four iterations, 30 subsets). No scatter correction was applied to any 
scan. Uniform attenuation correction was performed (attenuation coefficient = 
0.12 cm-1). The reconstructed data were post-filtered using a Butterworth filter 
(order 5, cut-off 0.5 of Nyquist frequency). Images were oriented along the 
orbitomeatal line and along the temporal axis. 
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3.4. Data assessment and statistical analysis: 
The two groups were combined and all studies were anonymised. The status of 
each scan was encoded and all identifying information was removed in the 
header file. Images were then assessed visually and semi-quantitatively. All the 
data were entered into a spreadsheet for analysis, and coding of scans was 
broken to reveal the NPSLE and control groups. Analysis was performed for the 
visual assessment method and the semi-quantitative assessment method. 
Statistical tests were considered significant if the p value was < 0.05.  
 
3.4.1 Visual assessment: 
Scans were reported by two Nuclear Medicine physicians who were blinded to 
the clinical status (NPSLE versus control) of the scans. The brain was divided 
into six cortical regions in each cerebral hemisphere (frontal lobe, parieto-
occipital lobe and temporal lobe), and six sub-cortical regions (basal ganglia, 
thalamus, and cerebellum). Visual assessment was done using two different 
color scales (French color table and ten band color table). The ten-band color 
table consisted of equally spaced discrete colors with maximum counts set to the 
maximal intensity voxel in the brain.  
 
Perfusion to a region was considered normal if there was homogenous perfusion 
with no reduced uptake compared to the contralateral side or adjacent grey 
matter. A region with inhomogeneous or reduced activity in at least two 
consecutive slices was considered as abnormal. Visual interpretation and 
statistical analysis were carried in the following steps: 
 
1. Overall impression: 
The overall impression for each scan was given, using the four point scale from A 
to D. Grade A = normal, grade B = probably normal, grade C = probably 
abnormal, and D = abnormal. 
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Receiver operator characteristic (ROC) analysis was applied to determine the 
cut-off point with the highest accuracy and the area under the ROC curve, 
considering the clinical diagnosis as the gold standard. The optimal sensitivity, 
specificity, positive predictive value (PPV), negative predictive value (NPV), and 
accuracy were calculated. Group differences between the NPSLE and the control 
group were analyzed with the Mann-Whitney U test. 
 
2. Severity score: 
Perfusion to each region was scored in a qualitative way using a scale from 0 to 
3. Scored 0=normal perfusion, 1=mild hypoperfusion, 2=moderate hypoperfusion, 
and 3=severe hypoperfusion. Then we calculated the total severity score (TSS) 
for each scan as the sum of the severity scores for all 12 regions. A ROC curve 
was applied to determine the cut-off point with the highest accuracy, and the area 
under the curve. Group differences between the NPSLE and the control group 
were analyzed with the Mann-Whitney U test. 
 
After that, we modified the total severity score by calculating the total score for 
the regions that had been scored as severity score 2 or 3. A ROC curve was 
applied to determine the cut-off point with the highest accuracy and the area 
under the curve. Group differences between the NPSLE and the control group 
were analyzed with the Mann-Whitney U test. 
3. SPECT patterns: 
The patterns of perfusion abnormality were classified into focal and diffuse using 
the following criteria: 
O Focal pattern if a single lesion or lesions were confined to one or two regions. 
O Diffuse pattern if lesions involved three or more regions.  
A kappa test was applied to assess the degree of agreement between the 
SPECT pattern (diffuse/focal) and the clinical classification (diffuse/focal). 
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3.4.2 Semi-quantitative assessment: 
The brain was divided into the same 12 regions described above. A ten-band 
color scale was utilized as described above. Each of these discrete colors 
represented a 10 % difference in the percentage of the maximal brain voxel 
counts. The interpretation was carried out in the following way: 
 
The color was compared with the contralateral region. A perfusion deficit was 
quantified on the side with the lower color intensity. The perfusion deficit was 
determined using the difference (in color bands) between the two hemispheres 
for the region on the ten-band scale. For example a differences of one color band 
was given a score of 1 for the region with the lower band, two color band 
differences a score of 2, etc. (See Figure 3.1) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: This figure demonstrates semi-quantitative scoring using a ten-band 
color scale. This scan shows reduced perfusion in the right parieto-occipital lobe 
with a difference of two color bands compared to the left site in two consecutive 
slices. Therefore, a score of two is given on the right parieto-occipital lobe. 
Right Left 
 26 
Then we calculated the total asymmetry score (TAS) for each scan. A ROC curve 
was applied to determine the cut-off point with the highest accuracy and the area 
under the curve. Group differences between the NPSLE and the control group 
were analyzed with the Mann-Whitney U test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27 
Chapter 4 - Results 
4.1. Study population: 
A total of 200 patients seen in the Rheumatology Division with SLE between 
1995 and 2009 were identified. Of these, 23 patients with neuropsychiatric 
manifestations underwent brain SPECT.  Nineteen patients met the criteria to be 
included in the study. The other four patients were not included as we couldn‟t 
find the clinical data for two of them, and the other two had technically poor 
images. Demographic data of patients with NPSLE is depicted in Table 4.1. All 
patients were female, with a mean age of 30.5 years (range 16-45). 
 
Table 4.1: Demographic data of NPSLE patients 
Patient 
No 
Date of birth Scan date Age Gender 
1 1965 2001 36 F 
2 1965 1995 30 F 
3 1988 2004 20 F 
4 1973 2003 30 F 
5 1968 2007 39 F 
6 1973 2003 30 F 
7 1976 2002 26 F 
8 1950 1995 45 F 
9 1963 1998 35 F 
10 1974 2006 32 F 
11 1973 2003 30 F 
12 1983 2004 21 F 
13 1975 2004 29 F 
14 1993 2009 16 F 
15 1967 2006 39 F 
16 1967 2006 39 F 
17 1968 2007 39 F 
18 1967 2008 29 F 
19 1976 2008 16 F 
        F = Female                                                                  
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The control group consisted of 14 males and five females, with a mean age of 
36.9 years (range 23-48). (Table 4.2) 
 
Table 4.2: Demographic data for the control group 
No. Date of birth Scan date Age Gender 
20 1954 2002 47 M 
21 1954 2002 48 M 
22 1954 2005 31 F 
23 1974 2001 26 M 
24 1956 2001 45 M 
25 1962 2002 39 M 
26 1968 2001 33 M 
27 1981 2005 23 M 
28 1957 2002 44 M 
29 1967 2002 34 M 
30 1972 2002 29 M 
31 1970 2001 31 F 
32 1965 2002 36 M 
33 1964 2001 37 F 
34 1970 2003 32 F 
35 1969 2001 32 M 
36 1965 2005 40 M 
37 1944 2001 57 M 
38 1963 2001 38 F 
   
       F = Female   
       M = Male 
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4.2. Clinical manifestations: 
Table 4.3 shows the ARA criteria used for the diagnosis of SLE in the patients. 
The frequency of the selected clinical criteria of SLE included antinuclear 
antibodies (16/19), arthritis (13/19), renal disorder (12/19), serositis (7/19), 
immunological disorder (7/19), discoid rash (6/19), oral ulcer (5/19), malar rash 
(5/19), photosensitivity (3/19), anti-DNA (3/19), and hematological disorders 
(2/19). 
 
Table 4.3: American College of Rheumatology criteria for SLE in the NPSLE 
group 
Patient 
No. SLE criteria 
1 Nephropathy, discoid lupus, ANF+ve, anti-DNA+ve 
2 Arthritis, oral ulcer, photosensitivity, ANF+ve 
3 Oral ulcer, photosensitivity, proteinuria , ANF+ve  
4 Discoid lupus, arthritis, serositis, thrombocytopenia, ANA +ve 
5 Arthritis, photosensitivity, pericardial effusion, ANF+ve 
6 Nephritis, malar rash, oral ulcer, pericarditis, ANF+ve 
7 Arthritis, ANF+, anti-DNA+, pancytopenia 
8 Discoid lupus, arthritis, ANF +ve, anti- DNA 
9 Arthritis, oral ulcer, nephritis, discoid rash 
10 Arthritis, protenuria, malar rash, ANF+ve 
11 Nephritis, arthritis, ANF+ve, anti- DNA+, anti-SM+ve 
12 Arthritis, discoid rash, pericardial effusion, proteinuria 
13 Nephritis, ANF+ve, anti- DNA+ve 
14 Nephritis, arthritis, proteinuria, serositis, ANF+ve,  
15 ANF+, arthritis, proteinuria 
16 Arthritis, ANF+, endocarditis  
17 Discoid lupus, malar rash, oral ulcer, ANF+  
18 Malar rash, arthritis, proteinuria,  ANF+ve, anti-DNA+ve 
19 Arthritis, serositis, malar rash ,protenuria, ANF+ve 
 
       ANF +ve = antinuclear factor positive  
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Table 4.4 shows the neuropsychiatric manifestations. All neuropsychiatric events 
occurred during, at, or after the first visit to the Rheumatology Division. With 
respect to neuropsychiatric events, a total of 10 out of the 19 syndromes 
occurred at least once. The most frequent syndromes were cognitive dysfunction 
(6/19), psychosis (4/19), mood disorders (3/19), cranial nerve palsy (3/19), 
seizures (3/19), movement disorders (2/19), cerebrovascular disease (2/19), 
meningitis (2/19) and others (6/19). According to the classification proposed by 
the American College of Rheumatology, 12 of the 19 patients were classified as 
having a diffuse syndrome, and the remaining seven had focal disease. 
 
Table 4.4: Neuropsychiatric manifestations in the NPSLE group 
Patient 
No. 
Neuropsychiatric manifestations 
  
Clinical 
classification 
1 Depression Diffuse 
2 Meningitis, left blinded eye Focal 
3 Cognitive dysfunction Diffuse 
4 Weakness, aphasia Focal 
5 Memory loss (cognitive dysfunction) Diffuse 
6 nystagmus , retinopathy , ataxia Focal 
7 Psychosis Diffuse 
8 Chorea Focal 
9 Headache, visual hallucination (psychosis) Diffuse 
         10 Psychosis, seizures, transient ischaemic attack Diffuse 
11 Loss of vision Focal 
12 Seizures Focal 
13 Meningitis Focal 
14 Depression, bilateral optic neuritis  Diffuse 
15 Depression, memory loss, seizures Diffuse 
16 Psychosis Diffuse 
17 Memory loss  Diffuse 
18 Cognitive dysfunction  Diffuse  
19 Cognitive dysfunction Diffuse  
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4.3. Visual assessment findings: 
A list of findings for the visual assessment method was given in Tables 4.5 
Table 4.5: Brain SPECT findings for the visual assessment for both groups 
No CD 
R-
fro 
L-
fro 
R-
par 
L-
par 
R-
tem 
L-
tem 
R-
bas 
L-
bas 
R-
thal 
L-
thal 
R-
cer 
L-
cer Ove TSS mTSS 
1 P 0 1 3 0 1 0 0 0 0 0 1 0 D 6 3 
2 P 0 1 0 0 0 1 0 0 0 0 0 0 B 2 0 
3 P 3 0 2 0 2 0 0 0 0 1 0 0 D 8 7 
4 P 2 2 2 2 2 2 0 0 0 0 1 0 C 13 12 
5 P 2 2 0 1 1 1 0 0 0 0 0 0 D 7 4 
6 P 0 0 2 0 1 0 0 0 0 0 0 0 C 3 2 
7 P 1 0 1 0 0 0 1 0 1 0 0 0 C 4 0 
8 P 1 2 1 2 1 0 0 0 0 0 1 0 C 8 4 
9 P 2 2 0 0 0 0 0 0 0 0 0 0 C 4 4 
10 P 2 2 2 2 1 2 0 0 0 0 0 0 D 11 10 
11 P 0 0 0 2 0 1 0 1 0 0 0 0 C 4 2 
12 P 1 1 1 1 2 2 0 0 0 0 0 0 C 8 4 
13 P 0 1 0 0 1 1 0 0 0 0 0 0 B 3 0 
14 P 2 2 2 2 2 1 2 0 1 0 0 0 D 14 12 
15 P 2 2 0 1 2 2 0 0 0 0 1 0 C 10 4 
16 P 1 1 0 0 0 2 0 0 0 1 2 0 C 7 4 
17 P 2 2 2 2 2 2 0 1 0 0 1 0 D 14 12 
18 P 2 2 1 2 2 0 1 0 0 0 0 0 D 10         8 
19 P 2 2 2 2 2 2 0 0 0 0 0 0 D 12 12 
20 N 0 0 0 0 0 0 0 0 0 0 0 0 A 0 0 
21 N 0 0 1 0 0 0 0 0 0 0 0 0 B 1 0 
22 N 1 0 1 1 0 0 0 0 0 0 0 0 B 3 0 
23 N 1 1 1 1 1 2 0 1 0 0 0 0 C 8 2 
24 N 0 0 0 1 0 1 0 0 0 0 0 0 B 2 0 
25 N 2 1 2 1 2 0 1 0 0 0 1 0 D 10 6 
26 N 0 0 0 0 0 0 0 0 0 0 3 0 B 3 3 
27 N 0 0 0 3 0 0 0 0 0 0 3 0 D 6 6 
28 N 2 1 1 0 1 0 0 0 0 0 0 0 C 5 2 
29 N 1 1 1 1 1 1 0 0 0 0 0 0 B 6 0 
30 N 0 0 1 0 1 1 1 0 0 0 1 0 B 5 0 
31 N 0 1 0 0 0 2 0 0 0 0 0 0 C 3 2 
32 N 1 1 2 1 1 1 0 0 0 0 0 0 C 7 2 
33 N 2 0 2 2 2 0 0 0 0 0 2 0 C 10 10 
34 N 1 1 1 1 0 1 0 0 0 0 0 0 B 5 0 
35 N 1 1 1 1 1 1 1 0 0 0 0 0 C 7 0 
36 N 0 1 0 1 0 0 0 0 0 0 0 0 B 2 0 
37 N 0 0 0 0 0 0 0 1 0 1 0 0 A 2 0 
38 N 0 0 1 0 1 0 0 0 0 0 0 0 A 2 0 
CD=clinical diagnosis, R=right, L= left, fro=frontal lobe, par=parieto-occipital lobe, tem=temporal lobe, 
bas=basal ganglia, thal=thalamus, cer=cerebellum, Ove=overall impression, TSS=total severity score, 
mTSS=modified total severity score. P= patient, N=normal. 0=normal perfusion, 1= mild hypoperfusion, 
2=moderate hypoperfusion, 3=severe hypoperfusion. A=normal, B=probably normal, C=probably abnormal, 
and D=abnormal. 
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For the visual assessment method, 160 regions with reduced perfusion were 
observed in both groups. Eighty-seven (54.4 %) of these areas were found on 
the right hemisphere, while 73 (45.6 %) were seen on the left side. Areas of 
hypoperfusion were found most frequently in the frontal regions (29.4 %), parieto-
occipital regions (28.8 %), and the temporal regions (26.3 %). Areas of 
hypoperfusion were seen less frequently in the cerebellum (6.8 %), basal ganglia 
(5.6%), and the thalamus (3.1 %).  
 
Of these 93 regions with defects were noticed in the NPSLE group. Fifty -one 
(54.8 %) of them were seen on the right side, while 42 (45.6 %) were on the left 
side. The most frequently affected were the frontal regions (31.1 %), temporal 
regions (28.0 %), and the parieto-occipital regions (24.7 %). Areas of 
hypoperfusion were seen less frequently in the cerebellum (6.5 %), basal ganglia 
(5.4 %), and the thalamus (4.3 %). (Table 4.6) 
 
Table 4.6: Regions of reduced perfusion seen on the visual assessment method             
Region of abnormality NPSLE group Control group 
Frontal 29 18 
Parieto-occipital 23 23 
Temporal 26 16 
Basal ganglia 5 4 
Thalamus 4 1 
Cerebellum 6 5 
Total  93 67 
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4.3.1. Overall impression: 
Grading of the brain SPECT using the overall score resulted in 10 being graded 
as grade A (normal), three as grade B (probably normal), 15 as grade C 
(probably abnormal), and 10 as grade D (abnormal). From these figures we 
found that no NPSLE patients were graded as grade A. Two NPSLE patients 
were graded as grade B, 9 as grade C, and eight as grade D. For the control 
group 10 were graded as grade A, one as grade B, six as grade C and two as 
grade D. 
 
A ROC analysis showed an acceptable diagnostic accuracy with an area under 
the curve of 0.76. A cut -off point at C showed 89 % sensitivity, 57 % specificity, 
68% positive predictive value, 84 % negative predictive value, and 74 % 
accuracy. (Figure 4.1) 
Figure 4.1: Overall impression using ROC curve 
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Group comparison showed that the NPSLE group had a significantly higher 
grade compared to the control group (P =0.001, Figure 4.2)     
 
Figure 4.2: Overall impression using Mann-Whitney U test for group differences 
 
 
 
      P = NPSLE group 
      N = control group 
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4.3.2. Severity score: 
Regarding the severity score, we found 295 (64.7 %) regions were graded as 
normal, 94 (20.6 %) as having a mild defect, 63 (13.8 %) as having a moderate 
defect, and 4 (0.9 %) regions as having a severe defect. From these figures, we 
found moderate defects in 51 (22.4 %) of regions of the NPSLE patient group, 
while moderate defects were found only in 12 (5.2 %) of regions of the control 
group. (Figure 4.3) 
 
Figure 4.3: SPECT perfusion severity scores for both groups  
 
  0 = normal, 1 = mild hypoperfusion, 2 = moderate hypoperfusion, 3 = severe    
  hypoperfusion 
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4.3.2.1. Total severity score (TSS): 
The maximum severity sum score for the all regions we found was 14, while the 
minimum score was zero. A ROC analysis resulted in an area under the curve of 
0.75. A cut-off point at seven showed 63 % sensitivity, 74 % specificity, 71 % 
positive predictive value, 67 % negative predictive value, and 68 % accuracy. 
(Figure 4.4)  
 
A cut-off point at four showed an arguably more acceptable sensitivity of 84 %, 
with a corresponding 47 % specificity, 62 % positive predictive value, 86 % 
negative predictive value, and 65 % accuracy.  
 
Figure 4.4: Total severity score (TSS) using ROC curve 
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Group comparison showed that the NPSLE group had a significantly increased 
total severity score compared to the control group (P= 0.008, Figure 4.5).       
 
Figure 4.5: Total severity score (TSS) using Mann-Whitney U test for group 
differences 
     
       
           P = NPSLE group 
           N = control group 
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4.3.2.2. Modified total severity score (mTSS): 
The maximum severity sum scores for the regions that had been scored as two 
or three was 12, while the minimum score was zero. A ROC analysis resulted in 
an area under the curve of 0.79. A cut-off point at three showed 74 % sensitivity, 
79 % specificity, 78 % positive predictive value, 75 % negative predictive value, 
and 76 % accuracy. (Figure 4.6)  
 
A cut-off point at two showed an arguably more acceptable sensitivity of 84 %, 
with a corresponding 58 % specificity, 67 % positive predictive value, 79 % 
negative predictive value, and 71 % accuracy.  
 
Figure 4.6: Modified total severity score (mTSS) using ROC curve 
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Group comparison showed that the NPSLE group had a significantly increased 
modified total severity score compared to the control group (P = 0.005, Figure 
4.7)       
 
Figure 4.7: Modified total severity score (mTSS): using Mann-Whitney U test for 
group differences 
 
       
        
          P = NPSLE group 
          N = control group 
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4.3.3. Correlation between SPECT pattern and the clinical classification: 
Agreement was found between the SPECT pattern and the clinical classification 
in 14 of the NPSLE group (73.6 %, kappa = 0.379). Eleven (92 %) of 12 patients 
with clinically diffuse syndromes had abnormal SPECT findings that were 
classified diffuse defect, whereas one patient (8 %) showed a focal SPECT 
pattern. On the other hand, for the seven patients who were classified as having 
a clinically focal syndrome, SPECT findings showed focal defects in three 
patients (43 %), and diffuse defects in four patients (57 %). 
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4.4. Semi-quantitative assessment findings: 
Table 4.7: Brain SPECT findings for the semi-quantitative assessment  
CD=clinical diagnosis R=right, L=left, fro=frontal lobe, par=parieto-occipital lobe, tem=temporal 
lobe, bas=basal ganglia, thal=thalamus, cer=cerebellum, TAS=total asymmetry score.0=no color 
difference, 1=one color difference to the contralateral side, and 2=two color differences to the 
contralateral side, etc. 
No CD R-fro L-fro 
R-
par 
L-
par 
R-
tem 
L-
tem 
R-
bas 
L-
bas 
R-
thal 
L-
thal 
R-
cer 
L-
cer TAS 
1 P 0 1 2 0 1 0 0 0 0 0 1 0 5 
2 P 0 1 0 0 0 1 0 0 0 0 0 0 2 
3 P 2 0 1 0 2 0 0 0 0 0 1 0 6 
4 P 0 1 0 1 0 0 1 0 0 0 1 0 4 
5 P 1 0 2 0 1 0 1 0 1 0 1 0 7 
6 P 1 0 1 0 1 0 0 1 0 0 1 0 5 
7 P 1 0 1 0 0 0 1 0 1 0 0 0 4 
8 P 0 1 0 1 0 0 0 0 0 0 1 0 3 
9 P 0 1 0 1 0 1 0 0 0 0 0 0 3 
10 P 1 0 1 0 0 1 0 0 0 0 1 0 4 
11 P 0 1 0 2 0 1 0 1 0 0 1 0 6 
12 P 0 1 0 1 0 1 1 0 0 0 1 0 5 
13 P 0 1 1 0 0 1 0 0 0 0 0 0 3 
14 P 1 0 1 0 1 0 2 0 1 0 1 0 7 
15 P 0 1 0 1 1 0 1 0 1 0 1 0 6 
16 P 0 1 0 1 1 0 1 0 0 1 1 0 6 
17 P 0 1 0 1 0 1 0 0 1 0 1 0 5 
18 P 0 1 0 1 1 0 1 0 0 0 0 0 4 
19 P 0 1 1 0 0 1 0 0 0 0 1 0 4 
20 N 0 1 1 0 0 0 0 0 0 0 0 1 3 
21 N 1 0 1 0 0 0 1 0 0 0 0 0 3 
22 N 1 0 1 0 1 0 0 0 0 0 0 0 3 
23 N 0 1 0 1 0 1 0 1 0 0 0 0 4 
24 N 0 0 0 1 0 1 0 0 1 0 0 0 3 
25 N 1 0 1 0 1 0 1 0 0 0 1 0 5 
26 N 0 0 0 1 1 0 0 0 0 0 1 0 3 
27 N 0 1 0 1 0 0 0 0 0 0 1 0 3 
28 N 1 0 1 0 1 0 0 1 0 0 0 1 5 
29 N 0 1 0 1 0 1 1 0 0 0 0 0 4 
30 N 0 0 1 0 0 0 1 0 0 0 1 0 3 
31 N 0 0 0 1 0 1 0 0 0 0 0 0 2 
32 N 0 1 1 0 1 0 0 0 0 0 0 0 3 
33 N 1 0 1 0 1 0 0 0 0 0 1 0 4 
34 N 0 1 0 0 0 0 1 0 0 0 0 0 2 
35 N 0 1 0 0 0 0 1 0 0 0 1 0 3 
36 N 0 1 0 1 0 0 1 0 0 0 0 0 3 
37 N 0 0 0 1 0 0 0 1 0 1 0 0 3 
38 N 0 1 1 0 0 0 0 0 0 0 0 0 2 
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The semi-quantitative asymmetry method resulted on a total of 145 regions with 
abnormalities in both groups. Eighty-five (58.6 %) of these areas were found on 
the right hemisphere, while 60 (41.4 %) were seen on the left side. Areas of 
hypoperfusion were found most frequently in the parieto-occipital regions (24.1 
%), frontal regions (22.8 %), and temporal regions (19.3 %), and less frequently 
in the cerebellum (14.5 %), basal ganglia (13.8 %), and the thalamus (5.5 %).Of 
these 82 regions were noticed for the NPSLE group, most frequently in the 
frontal regions (23.1 %), parieto-occipital regions (21.9 %), and temporal regions 
(19.6 %), and less frequently in the cerebellum (15.9 %), the basal ganglia (12.1 
%), and the thalamus (7.4 %). (Table 4.8) 
 
Table 4.8: Regions of asymmetrical perfusion seen on the semi-quantitative 
method 
Region of abnormality NPSLE group Control group 
Frontal 19 14 
Parieto-occipital 18 17 
Temporal 16 12 
Basal ganglia 10 10 
Thalamus 6 2 
Cerebellum 13 8 
Total 82 63 
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The maximum asymmetry sum score for all regions we found was seven, while 
the minimum score was two. A ROC analysis resulted in an area under the curve 
of 0.80. A cut-off point at 4 showed 79 % sensitivity, 74% specificity, 75 % 
positive predictive value, 78 % negative predictive value, and 76 % accuracy. 
(Figure 4.8)  
 
Figure 4.8: Total asymmetry score (TAS) using ROC curve 
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Group comparison showed that the NPSLE group had a significantly increased 
asymmetrical score compared to the control group. (Figure 4.9) 
 
Figure 4.9: Total asymmetry score (TAS) using Mann-Whitney U test for group 
differences 
 
 
      P = NPSLE group 
      N = control group 
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Table 4.9 summarized the optimal results that obtained from the ROC curve for 
the visual method (overall impression, total severity score and modified total 
severity score) and the semi-quantitative method (total asymmetry score). 
 
 Table 4.9: optimal cut-off point for the different techniques 
Technique Optimal cut-
off point 
Sensitivity Specificity PPV NPV Accuracy 
Overall  C 0.89 0.57 0.68 0.84    0.73 
TSS 7 0.63 0.73 0.70 0.66    0.68 
mTSS 3 0.73 0.78 0.77 0.75    0.76 
TAS 4 0.78 0.73 0.75 0.77    0.76 
       
 Overall = overall impression 
 TSS = total severity score 
 mTSS = modified total severity score 
 TAS = total asymmetry score 
 PPV = positive predictive value 
 NPV = negative predictive value 
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Chapter 5 - Discussion 
 
One of the most important and disabling complications of SLE is the involvement 
of the central nervous system, which comprised a heterogonous group of clinical 
presentations, including focal neurological events or more diffuse patterns. 
However, no single mechanism can account for the broad spectrum of these 
manifestations and no test has proved consistently reliable in the diagnosis of 
NPSLE. The rationale for using SPECT to assess neuropsychiatric 
manifestations in SLE patients can be based on evidence that CNS disease in 
SLE may be secondary to abnormalities in the cerebral vessels, or that locally 
decreased neurological function will lead to decreased perfusion via 
autoregulation. However, the accuracy of SPECT has showed variable results, 
which could be attributed to different factors, such as the study design, as well as 
the different methods of image analysis (interpretation).12 13 14 15 48 57  
 
In this study we found that: 
1. SPECT was able to separate patients with active NPSLE from normal controls, 
2. Compared to a visual impression, similar results were obtained using visual or 
semi-quantitative scores.  
3. In patients with active NPSLE a significant correlation exists between the 
clinical disease pattern and perfusion patterns with SPECT. 
 
The first finding of this study was that SPECT was able to separate patients with 
active NPSLE from normal controls. For the visual impression, we used a four-
point scale which reflected the diagnosis as well as our level of certainty. Grade 
A (normal) and grade D (abnormal) indicate a high level of certainty, which were 
shown to have a high NPV (100 %) and PPV (60 %) respectively. Probability 
grades B and C are more equivocal. Although the diagnosis of NPSLE in all 
cases graded as C or D still resulted in a good sensitivity (89 %), specificity was 
moderate (57 %). 
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The results that we obtained from the ROC curve analysis showed that a cut-off 
point at C gave the best results. That means grade A and B were considered as 
normal and grade C and D as NPSLE. These results showed an area under the 
curve of 0.76 which is acceptable. The high sensitivity (89 %) obtained from this 
analysis, resulted in an ability to diagnose most of the NPSLE patients (17 out of 
19), however we failed to identify a significant abnormality in two patients of the 
NPSLE group. Interestingly, those two patients were the only cases who 
presented with CNS symptoms of meningitis. That is in contrast to Kovacs et al 
and Zhang et al.56 57 where SPECT was found to be abnormal in patients with a 
septic meningitis. The reason for this discrepancy is unclear, but it could be due 
to the clinical condition of those patients. The high sensitivity in our study is 
comparable with the results of Longo et al.48 where the sensitivity of SPECT was 
found to be 85 % using a similar four-point scale. Similar results were also seen 
in other studies; although they did not use a four-point scale for their 
intepretation.12 13 
 
Using the optimal cut-off point, this technique however showed a relatively low 
specificity (57 %). This indicates the high number of false positive scans that 
were reported (9 out of 19). These results demonstrate that the interpreters were 
unable to report many control scans as normal; even though it was known that 
half of the scans were from the control group. It therefore seems to be easer to 
detect abnormalities in the NPSLE group, than to exclude abnormalities in the 
control group. The moderate specificity in our study is similar to Russo et al. 
where specificity was 69 %.12 However direct comparison with other studies is 
problematic, as we used a normal control group in our study, while most of 
control groups in previous studies were SLE patients with inactive NP 
manifestations or SLE patients without NPSLE. Only one study done by Sanna et 
al used healthy volunteers. That study showed homogonous and symmetrical 
perfusion for all the control cases.15 This discrepancy with Sanna et al, could 
however be at least in part related to the fact that they did not anonymised both 
groups (control & NPSLE) and report them blindly as was done in this study. 
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In our study, we found that reduced perfusion was found more frequently in the 
frontal, parieto-occipital, and temporal regions, while the basal ganglia, thalamus 
and cerebellum were less frequently affected. This result is in agreement with Lin 
et al.14 This could be due to fact that the major pathogenesis in SLE patients is 
probably related to a vasculopathy with thickening of the intima and fibrinoid 
degeneration, mainly of the small blood vessels. In addition to that, the 
abnormalities resembling embolic disease have been reported in approximately 
40 % of SLE patients and since the territory of the middle cerebral artery which 
supplies mainly the cortical regions is at a higher risk for cerebral embolism than 
others, a relation between these two observations may exist.80 
 
The second finding of this study, that similar results to the visual impression were 
obtained using the visual scoring and the semi-quantitative scoring. These all 
gave a result that statistically was no different from the overall impression. From 
the analysis, we found that the TAS allowed the most accurate classification with 
an area under the curve of 0.80, while TSS gave the least accuracy with an area 
under the curve of 0.75. However, the difference between all these analysis 
methods was not significant (P > 0.05). It could be argued that, these 
comparisons do not give a complete picture, as the ROC curves might cross at a 
particular false-positive fraction (FPF). Therefore, a method with a greater area 
under the curve (AZ) might actually have a worse sensitivity for a given FPF. 
 
For the visual scoring, we evaluated the relative cerebral blood flow for each 
region visually in a qualitative way using a severity score from 0 (normal) to 3 
(severe hypoperfusion), in order to investigate whether this raised the accuracy 
of our interpretation. We found that 16/19 of the NPSLE patients had at least one 
area of moderate or severe hypoperfusion, while three patients did not have any 
areas of moderate or severe hypoperfusion. Of the second group, 8/19 of the 
controls had at least one area of moderate or severe hypoperfusion, while the 
rest had only areas of normal or mild hypoperfusion. If we simply consider scans 
with areas of moderate or severe hypoperfusion as positive, we will get a 
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sensitivity of 84 % and a specificity of 57 %, which is similar to our overall 
impression score. However, an important draw back of this method is that the 
definitions of mild, moderate, and severe is completely subjective.  
 
After that, we calculated the total severity score for each scan, assuming that 
patients with NPSLE should have more total severity score than the control 
group. An ROC curve analysis was applied which demonstrated an area under 
the curve of 0.75. A total severity score of seven or more gave the best results 
with a sensitivity of 63 %, specificity of 73 %, and accuracy of 68 %. Similar 
accuracy (68 %) for the TSS was noticed at the cut-off point eight, where the 
sensitivity dropped from 63 % to 52 %, while the specificity increased from 73 % 
to 84 %. 
 
The lower sensitivity using the visual scoring (TSS) is due to the fact that many of 
the NPSLE patients had a total severity score of four or less. That could be 
explained in two ways; firstly, those patients might have a mild form of the 
disease, and patients with severe disease should be expected to have more 
severe perfusion deficits.81 This statement could tested if we had the opportunity 
to assess the clinical severity of the disease. However, this was not possible 
because the retrospective nature of the study making this information 
unavailable. A second explanation could be that the interpreters had difficulty 
differentiating mild hypoperfusion in NPSLE from normal perfusion, and scoring 
areas with mild hypoperfusion with a zero score, rather than one would 
underestimate the total severity score. Lonborg et al. stated that interpreting by 
eye alone would not be able to detect all rCBF abnormalities, especially if they 
are mild.78 When we re-analyzed the data considering areas that had mild 
hypoperfusion as having a score of zero using the mTSS, the ROC curve 
analysis resulted in area under the curve of 0.79 which is higher than that of the 
TSS, although the difference was not significant. At a cut-off point of three, the 
mTSS improved over the TSS, achieving 76 % accuracy. The sensitivity was 
increased from 63 % to 73 %, and the specificity increased from 73 % to 78 %.  
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It is therefore likely that areas of mild hypoperfusion are often a normal variant 
rather than mild disease, and their exclusion from a combined score can 
enhance specificity, without a loss of sensitivity. 
 
The improvement in accuracy using the mTSS is related to the fact that moderate 
and severe lesions were seen in most of the NPSLE group (16/19) compared to 
about half of the control group (8/19), while mild lesions were seen in all of the 
NPSLE group (19/19) and almost all of the control group (18/19). A similar 
accuracy (76 %) for the mTSS was noticed at the cut-off point four, where the 
sensitivity dropped from 73 % to 68 %, while the specificity increased from 78 % 
to 84 %. However, it can be argued that the cut-off point at seven for the TSS or 
at three for the mTSS will be clinically more useful, as it is more important to 
detect NPSLE than to exclude abnormalities in a normal person. 
 
Finally, we can conclude that the presence of a severe defect or more than one 
moderate defect is unlikely in a normal person. In addition to that, differentiating 
severe or moderate defects from normal perfusion is much easier than 
differentiating mildly reduced perfusion from normal perfusion. Moreover, the 
TSS and mTSS could not do better than simply defining positivity based on 
moderate and severe lesions, so a combined score like this does not seem to be 
that useful. 
 
Compared to visual interpretation, the accuracy did not improve by using semi-
quantitative scoring with the TAS. The ROC curve analysis resulted in area under 
the curve (0.80) at a cut-off point of 4 with 76 % accuracy. This resulted in a 
sensitivity of 78 %, as we failed to identify four out of 19 NPSLE patients (22 %). 
That could be explained by the fact that this scoring system is based on 
asymmetry, while abnormalities could be present bilaterally. For example, you 
might have an abnormality in both frontal lobes, but with a color difference 
between the right and left of only one color, and therefore a score of only one.  
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As a second example, you might have an abnormality in the anterior part of the 
right frontal lobe and an abnormality in the posterior part of the left frontal lobe. 
Therefore, we would be able to give a score for either the anterior or the posterior 
lesions depending on the extent of abnormality. Therefore, dividing each 
hemisphere for more regions such as anterior frontal, posterior frontal, anterior 
parietal, posterior parietal ……etc, might be more useful. This would however 
make the method more time consuming. 
 
When we analyzed the semi-quantitative results for the individual scores, we 
noticed that all scans had at least one area with a score of one or more, so we 
get 100 % sensitivity and 0% specificity. However, when we consider scans with 
at least one area with a score of 2 or more, we found none of the control group 
had a score of 2 or more (100 % specificity), but only 5/19 of the NPSLE patients 
(26 % sensitivity) had a score of 2 or more. Therefore, further research using a 
20 band scale might be useful to determine the sensitivity and specificity of an 
equivalent of a score of 1.5. 
 
The reported sensitivity of SPECT in active SLE using semi-quantitative methods 
based on ROI varied from 71 % to 88 %.48 54 58 That supports our assumption 
about the capability of the method we used to give similar results. The 
reasonable specificity in this analysis indicates that asymmetrical involvement is 
less likely in the control group. Asymmetry was also seen more frequently in 
cortical areas compared to subcortical areas.  
 
Although using the semi-quantitative score achieved the best result, however the 
difference is not statistically significant. However, it provides an objective method 
of interpretation that does not require a subjective decision as to what is mild, 
moderate or severe. In addition to that, it require less time, which can be useful in 
a busy department, and does not require special software or skills, so it would be 
ideally suited for routine practice and can be applied anywhere, even in centers 
with little brain SPECT experience and without special software. 
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The third finding of this study was that a significant correlation exists between the 
clinical disease pattern and perfusion patterns with SPECT. Correlations 
between the pattern of the perfusion defects and the clinical syndromes have 
been investigated in many studies. In this study, we found that the percentage 
agreement between the SPECT and the clinical pattern is 92 % in patients with 
diffuse disease. That is in agreement with most of the studies.12 57 77 In patients 
with clinically focal disease, the SPECT pattern agreed in only in 43 %. That is in 
agreement with Russo et al.12 In contrast to that Kovacs et al. found that SPECT 
agreed in all cases they reported.56 This discrepancy could however be due to 
small number of only 4 patients that were included in their study. Although, the 
clinical importance of this finding is unclear, the differentiation of a diffuse from a 
focal syndrome may be important for the management and the clinical outcome 
of the patient, considering that it is not easy to distinguish these processes by 
clinical presentation. 
 
Limitations of the study: 
 
Our study has several limitations, which are: 
 
 Neuropsychiatric SLE is a difficult condition to define clinically even after 
the development of the nomenclature of the American College of 
Rheumatology (ACR) in 1999, as the condition needs in addition to proper 
clinical evaluation, a number of investigations which includes laboratory 
and imaging investigations. Therefore, an absolute „gold standard‟ was not 
available to assess the interpretation of the SPECT. 
 
 The retrospective nature of the study resulted in additional clinical data, 
such as the clinical assessment of the disease severity, being unavailable. 
This information, if available, could have been related to the severity of the 
perfusion abnormalities. 
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 This study did not compare active NPSLE to inactive NPSLE or to patients 
with SLE without known NPSLE. This may be a more realistic 
representation of the clinical situation. However a comparison like this 
may also be complicated by the presence of subclinical NPSLE giving 
apparent “false positive” results and falsely lowering the specificity. This is 
less of a concern using normal controls. 
 
 The differences between the NPSLE group and the control group, in terms 
of age and sex is a potential confounding factor. Denays et al. found that 
there is slight tendency after 15 or 20 years for relative decline in the 
cerebral areas in healthy volunteer, particularly in the prefrontal and motor 
areas.82  We tried to make both groups comparable in terms of age and 
sex. Although, there was a difference in the mean age between both 
groups, this wasn‟t statistically significant (P = 0.67). However, a statistical 
difference was found in sex (P = 0.0001), as males were predominant in 
the control group. 
 
 The differences in the imaging instruments that we used is also a potential 
confound of the study, as five scans from the NPSLE were imaged using a 
GE Hawkeye gamma camera, while the rest of the NPSLE group and all 
controls were imaged using an Elscint Helix gamma camera. 
 
 
Conclusion and recommendations: 
Tools to assess brain function are clearly needed in numerous conditions which 
lack definitive diagnostic or specific patterns. In this study we evaluated our 
interpretation of brain SPECT in NPSLE using visual and semi-quantitative 
methods. The study showed that brain SPECT is able to diagnose active NPSLE 
with high sensitivity and moderate specificity. No significant differences were 
seen between the four techniques used.  
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The interpretation of SPECT images is difficult, and neuro-imaging studies are 
complementary and useful examinations in the evaluation of neurological 
involvement in patients with NPSLE. Furthermore, we recommend the use of a 
simple semi-quantitative score as an adjunct to a visual assessment. This 
requires little time, and does not require special software or skills, so it would be 
ideally suited for routine practice, especially in centers with little experience of 
brain SPECT in NPSLE, and lacking special software, normal databases and 
skills. 
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Appendix 1: The 1982 revised criteria for SLE (adapted from Arthritis Rheum 1982; 
25:1271–7) 
 
Criteria Definition 
Malar rash Fixed erythema, flat or raised over the malar eminence, tending to spare the 
nasolabial folds 
Discoid rash Erythematous raised patches with adherent keratotic scaling and follicular 
plugging; atrophic scaring may occur in older lesions 
Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or 
physician observation 
Oral ulcer Oral or nasopharyngeal ulceration, usually painless, observed by a 
physician 
Arthritis  Nonerosive arthritis involving 2 or more peripheral joints, characterized by 
tenderness, swelling, or effusion 
Serositis a) Pleuritis – convincing history of pleuritic pain or rub heard by a   
     physician or evidence of pleural effusion 
       OR 
b) Pericarditis – documented by ECG or rub or evidence of   
     pericardial effusion 
Renal disorder a) Persistent protenuria greater than 0.5 gram per day or greater than  
     3+ if quantification not performed 
       OR 
b) Cellular cast – may be red cell, hemoglobin, granular , tubular, or  
     mixed 
Neurologic    
disorder 
a) Seizures – in the absence of offending drugs or known metabolic  
    derangement; e.g.,uremia,ketoacidisis,or electrolytes imbalance 
      OR 
b) Psychosis – in the absence of offending  drugs or known metabolic  
     derangement; e.g.,uremia,ketoacidosis,or electrolytes imbalance 
Hematologic  
disorder 
a) Hemolytic anemia – with reticulocytosis 
          OR 
b)  Leucopenia – less than 4,000/mm
3
 total on 2 or more occasions 
         OR 
c) Lymphopenia – less than 1,500/mm
3
 on 2 or more occasions 
         OR 
d) Thrombocytopenia – less than 100,000/mm
3
 in the absence of     
     offending drugs 
Immunologic  
disorder 
a) Positive LE cell preparation 
         OR 
b) Anti- DNA: antibody to native DNA in abnormal titer 
         OR 
c) Anti – Sm : presence of antibody to Sm nuclear antigen 
        OR 
d) False positive serologic test for syphilis 
Antinuclear  
antibody 
An abnormal titer of antinuclear antibody by immunofluorescense or an 
equivalent assay at any point in time and in the absence of drugs known to 
be associated with” drug-induced lupus” syndrome 
 
 
